Neuroscience Foundations for Psychiatry: Neurotransmitters, Circuits, and Clinical Correlates

Why Neuroscience Matters for Clinical Psychiatry

The most powerful tool in psychopharmacology is understanding mechanism. When you know that D2 blockade in the nigrostriatal pathway causes extrapyramidal side effects (EPS) while D2 blockade in the mesolimbic pathway treats positive symptoms of psychosis, antipsychotic selection becomes intuitive rather than arbitrary. When you understand that SSRIs increase serotonin availability at 5-HT1A and 5-HT2A receptors via reuptake inhibition, prescribing high-dose fluoxetine for OCD (which requires near-maximal SERT occupancy) or low-dose paroxetine for generalized anxiety disorder makes sense. Understanding receptor pharmacology explains side effects too: why mirtazapine causes weight gain (5-HT2C antagonism) and sedation (H1 antagonism), why bupropion does not impair sexual function (dopamine, not serotonin), why some antipsychotics but not others cause tardive dyskinesia (dopamine antagonism duration and occupancy).

Neuroscience vocabulary becomes the language of clinical decision-making. This chapter provides that vocabulary—the fundamental neural systems that, when dysregulated, underlie psychiatric illness, and when targeted, respond to our medications.

The Neuron and Synaptic Transmission

All psychiatric medication works at the synapse. The basic anatomy: a presynaptic neuron releases neurotransmitter from vesicles into the synaptic cleft; the neurotransmitter diffuses across the ~20-nanometer gap and binds to receptors on the postsynaptic membrane, initiating electrical or chemical cascades in the receiving neuron. The postsynaptic effect depends on receptor type: some receptors are ionotropic (ligand-gated ion channels, fast synaptic transmission) and some are metabotropic (G-protein coupled receptors, slower but more diverse intracellular effects). Neurotransmitter action is terminated through three mechanisms: reuptake (transporter proteins recycle the molecule back into the presynaptic terminal), enzymatic degradation (e.g., monoamine oxidase breaks down dopamine, serotonin, norepinephrine), and diffusion (molecules drift away from the cleft).

Psychiatric medications target each of these steps:

Two pharmacological concepts matter for understanding side effects: receptor affinity (how strongly a drug binds to a receptor, measured as Ki in nanomolar concentrations) and receptor occupancy (the percentage of receptors bound at a given dose). A drug with high affinity for a receptor will occupy many of those receptors at modest doses, causing potent effects. Ziprasidone has high affinity for serotonin 5-HT2A (Ki ~0.4 nM) but lower affinity for histamine H1 (Ki ~21 nM), so it causes less sedation and weight gain than olanzapine, which has equal affinity for both. Understanding these pharmacological fine points transforms the art of medication selection into precision medicine.

The Serotonin (5-HT) System

Anatomy and Functions

The serotonergic system is anatomically concentrated but functionally distributed. The vast majority of serotonin neurons reside in two midline nuclear clusters: the dorsal and median raphe nuclei of the brainstem. From this compact region, serotonergic axons project widely to the cortex, limbic system (amygdala, hippocampus), striatum, brainstem (where they modulate pain, sleep, appetite), and spinal cord. This anatomical pattern—a small source with widespread output—is characteristic of neuromodulatory systems.

Serotonin's functional roles are equally diverse: it regulates mood, anxiety, impulse control, aggression, pain perception, appetite, sexual function, and sleep-wake cycling. Serotonin cells are exquisitely sensitive to stressors, and chronic stress suppresses serotonergic neurotransmission—one mechanism linking environmental adversity to depression.

Key Receptor Subtypes and Clinical Relevance

Serotonin has at least 14 distinct receptor subtypes (5-HT1 through 5-HT7), and understanding the clinically relevant ones is essential:

5-HT1A receptors exist as presynaptic autoreceptors (on serotonin neurons themselves, where activation reduces serotonin release) and postsynaptic receptors (in cortex, hippocampus, amygdala). SSRIs acutely increase synaptic serotonin, activating presynaptic 5-HT1A autoreceptors and paradoxically reducing further serotonin release—this is the mechanism of initial activation and anxiety observed in the first 1–2 weeks of SSRI treatment. Over weeks, desensitization of autoreceptors occurs, and the net effect becomes anxiolytic and antidepressant. Postsynaptic 5-HT1A activation in the amygdala and hippocampus mediates anxiety reduction and is the mechanism of action of buspirone, a partial 5-HT1A agonist used for generalized anxiety disorder.

5-HT2A receptors are located in cortex (especially visual cortex) and have multiple clinical relevances. Antagonism at 5-HT2A is a core mechanism of antipsychotic action—all second-generation antipsychotics have significant 5-HT2A antagonism. 5-HT2A agonism, by contrast, is the mechanism of action of classical hallucinogens (LSD, psilocybin), explaining why psychotic patients sometimes experience exacerbation of symptoms with serotonergic drugs. Low-potency first-generation antipsychotics (chlorpromazine, thioridazine) have minimal 5-HT2A antagonism and are therefore less effective for psychosis than second-generation antipsychotics, which are balanced D2 and 5-HT2A antagonists.

5-HT2C receptors are found in the hypothalamus and regulate appetite and energy homeostasis. Antagonism of 5-HT2C (by olanzapine, mirtazapine, quetiapine) causes weight gain and metabolic dysfunction—a major limiting side effect of many psychiatric medications. Conversely, 5-HT2C agonists are in development as antipsychotics with lower metabolic risk.

5-HT3 receptors are ionotropic (ligand-gated ion channels) located in the chemoreceptor trigger zone and gastrointestinal tract. SSRIs increase synaptic serotonin and activate 5-HT3 receptors, causing nausea and GI upset in a subset of patients—the "serotonin syndrome lite" of initial GI side effects. 5-HT3 antagonists (ondansetron) are sometimes co-prescribed to mitigate this.

Clinical Correlates: Depression and Serotonin

The serotonin hypothesis of depression—that depression results from serotonin deficiency—has been foundational in psychiatry since the 1950s. SSRIs and SNRIs are the first-line treatment for depression because they increase synaptic serotonin. However, the hypothesis is incomplete: many depressed patients respond poorly to serotonergic monotherapy, and serotonin is only one of multiple dysregulated systems in depression (dopamine and norepinephrine deficiency, HPA axis hyperactivity, neuroinflammation, and reduced neuroplasticity all contribute). Understanding serotonin's role without overinterpreting it as the sole deficit allows more sophisticated prescribing: a patient with depression and poor motivation might benefit from bupropion (dopamine reuptake inhibitor) in addition to or instead of an SSRI.

In OCD, serotonergic dysfunction is thought to underlie the disorder, and SSRIs are first-line. Notably, OCD requires higher doses and longer duration (8–12 weeks) than major depression to show benefit, suggesting that OCD represents more severe or treatment-resistant serotonergic dysfunction. The mechanism may relate to excessive 5-HT2A signaling in orbitofrontal cortex and anterior cingulate cortex (regions hyperactive in OCD).

In anxiety disorders, SSRIs target both the serotonin deficit itself and (via desensitization of presynaptic autoreceptors over weeks) allow greater postsynaptic 5-HT1A activation, reducing amygdala reactivity and anxiety.

The Dopamine System

The Four Dopamine Pathways

Dopamine is synthesized in a discrete set of midbrain neurons (ventral tegmental area, VTA, and substantia nigra) and organized into four anatomically distinct pathways. This organizational principle is critical because dopamine blockade in one pathway can treat illness while blocking it in another causes side effects.

The clinical tragedy of dopamine-blocking antipsychotics is that they treat psychosis (mesolimbic benefit) while blocking dopamine in the nigrostriatal system (causing EPS) and tuberoinfundibular system (causing prolactin elevation). This accounts for the intolerable side effect profile of high-potency first-generation antipsychotics (haloperidol, fluphenazine) in many patients. Second-generation antipsychotics offer modest improvement: they have slightly higher affinity for mesolimbic and mesocortical dopamine relative to nigrostriatal, but the separation is incomplete.

D2 Receptor Occupancy Theory

An enduring principle in antipsychotic pharmacology: antipsychotic efficacy requires 60–80% D2 receptor occupancy in mesolimbic and mesocortical regions. Below 60%, insufficient dopamine blockade; above 80%, escalating EPS risk without further antipsychotic benefit. This principle explains dose ceiling effects in antipsychotics: increasing haloperidol beyond 10–15 mg/day yields no additional antipsychotic benefit but greatly increases EPS risk.

This occupancy principle also explains why antipsychotic choice matters: aripiprazole (a partial agonist rather than antagonist) occupies D2 receptors but partially activates them, keeping the system in a more physiologic range and reducing both EPS and hyperprolactinemia relative to full antagonists. Quetiapine, conversely, has rapid D2 dissociation kinetics, meaning receptors remain unblocked much of the time—this may explain its lower EPS risk at therapeutic doses, though it contributes to weight gain through other mechanisms (H1, alpha-1, and muscarinic antagonism).

Clinical Correlates: Psychosis, ADHD, Addiction, and Parkinson's Disease

The dopamine hypothesis of schizophrenia—that positive symptoms result from mesolimbic dopamine excess—predicts and explains antipsychotic action. It is incomplete, however, because it does not account for negative symptoms and cognitive deficits, which relate more to mesocortical hypoactivity. Some evidence suggests that D2 antagonists may worsen negative symptoms by further reducing mesocortical dopamine; this motivates interest in dopamine agonists, which preferentially activate autoreceptors on serotonergic neurons and reduce mesolimbic dopamine without further impairing cortical dopamine.

ADHD involves prefrontal dopamine deficiency (and norepinephrine deficiency). Stimulants (methylphenidate, amphetamine), which are dopamine and norepinephrine reuptake inhibitors, are first-line. Bupropion (NDRI—norepinephrine/dopamine reuptake inhibitor) is an effective non-stimulant alternative. Atomoxetine (selective norepinephrine reuptake inhibitor) is another option.

Substance use disorders and addiction involve dysregulation of the mesolimbic reward pathway. Dopamine agonists (bromocriptine) or partial agonists (aripiprazole) are sometimes used to restore dopaminergic tone and reduce cravings. Opioid antagonists (naltrexone) block the rewarding effects of opioids and alcohol, reducing relapse.

Parkinson's disease results from degeneration of nigrostriatal dopamine neurons (>80% cell loss at symptom onset). Levodopa (converted to dopamine in the brain) or dopamine agonists (bromocriptine, pramipexole, ropinirole) are mainstays of treatment. Psychiatric side effects of Parkinson's medications include impulse control disorders (gambling, hypersexuality), psychosis, and mood dysregulation from excess mesolimbic dopamine stimulation.

The Norepinephrine (NE) System

Anatomy and Functions

Norepinephrine neurons originate in a small brainstem region, the locus coeruleus (LC), and project diffusely to cortex, limbic system (amygdala, hippocampus), cerebellum, and spinal cord. The LC is the brain's alarm system: activity increases during arousal, attention, and stress. NE release increases heart rate, blood pressure, and vigilance—the sympathetic nervous system effects. The LC is exquisitely sensitive to threat and uncertainty; chronic stress leads to LC hyperactivity and noradrenergic hyperresponsiveness, a core feature of anxiety and PTSD.

NE Receptor Subtypes

Alpha-1 receptors are postsynaptic; their antagonism causes orthostatic hypotension (blood pressure drop upon standing) and dizziness. Medications with significant alpha-1 antagonism include tricyclic antidepressants (TCAs), some low-potency antipsychotics (chlorpromazine, clozapine), and trazodone. In elderly patients, alpha-1 antagonism increases fall risk.

Alpha-2 receptors function as autoreceptors on noradrenergic terminals; their activation reduces norepinephrine release. Alpha-2 agonists (clonidine, guanfacine) are used in ADHD (improving prefrontal NE and dopamine), anxiety, and opioid withdrawal (reducing LC rebound hyperactivity). Alpha-2 antagonism (by mirtazapine) increases NE release, contributing to its antidepressant and sleep-promoting effects.

Beta receptors are primarily involved in peripheral sympathetic effects (heart rate, blood pressure). Central beta antagonism (propranolol) can reduce anxiety and tremor—useful in performance anxiety or social anxiety disorder.

Clinical Correlates: Depression, Anxiety, PTSD, and ADHD

Depression involves norepinephrine deficiency in addition to serotonin deficiency. SNRIs (venlafaxine, duloxetine) and TCAs target both systems. Bupropion boosts dopamine and NE. Some evidence suggests that NE-selective drugs (atomoxetine, desipramine) are less effective for depression than dual-action agents, implying that serotonin contribution is important.

Anxiety disorders involve LC hyperactivity. SSRIs and SNRIs reduce LC firing over time through complex mechanisms (receptor feedback, BDNF upregulation). Alpha-2 agonists (guanfacine, clonidine) directly activate LC autoreceptors and suppress firing acutely. Benzodiazepines enhance GABA (discussed below), which inhibits LC neurons and rapidly quells anxiety, though tolerance develops.

PTSD involves both hyperactive LC (hyperarousal, hypervigilance) and reduced prefrontal cortex regulation of the amygdala. SSRIs and SNRIs are first-line; some evidence supports prazosin (alpha-1 antagonist) for nightmares, possibly by reducing noradrenergic drive to the amygdala during REM sleep. Alpha-2 agonists (clonidine, guanfacine) may help with hyperarousal in complex PTSD.

ADHD involves prefrontal NE and dopamine deficiency. Stimulants and atomoxetine (norepinephrine reuptake inhibitor) increase prefrontal NE availability, improving executive function, attention, and impulse control. Alpha-2 agonists (guanfacine, clonidine) have modest benefit.

GABA and Glutamate — The Yin and Yang

GABA: The Primary Inhibitory Neurotransmitter

GABA is the main inhibitory neurotransmitter in the brain. GABA-A receptors are ligand-gated chloride channels: GABA binding opens the channel, hyperpolarizing the neuron and making it less likely to fire. GABA-A receptors are the targets of the most widely prescribed psychiatric drugs: benzodiazepines (alprazolam, lorazepam), barbiturates (phenobarbital), and Z-drugs (zolpidem, zaleplon). Benzodiazepines and Z-drugs are allosteric modulators at the GABA-A receptor—they don't directly activate the channel but enhance GABA's effects when GABA itself is present. This allosteric mechanism is why benzodiazepines are "selective": they enhance inhibition where GABA is active (relevant brain regions) rather than globally suppressing the brain.

GABA-B receptors are G-protein coupled receptors; their agonist, baclofen, is used for muscle spasticity and has some evidence in alcohol use disorder (reducing craving and protracted withdrawal symptoms). GHB (gamma-hydroxybutyrate), a GABA-B agonist, is used for cataplexy in narcolepsy but has abuse potential.

Clinical Correlates: Anxiety, Epilepsy, Alcohol and Benzodiazepine Withdrawal

The GABA hypothesis of anxiety suggests that anxiety disorders involve GABA deficiency or dysfunction. Benzodiazepines provide rapid anxiolytic and sedative effects, making them highly effective for acute anxiety, panic, and insomnia. However, tolerance develops (particularly to anxiolytic effects), and dependence is substantial—chronic benzodiazepine use often leads to escalating doses and difficulty discontinuing. Therapeutic benzodiazepines are therefore reserved for short-term use or chronic use in refractory anxiety unresponsive to SSRIs.

Alcohol and benzodiazepines both enhance GABA-A function. Chronic use leads to GABA-A receptor downregulation (tolerance) and glutamate upregulation (allostatic adaptation). Upon abrupt cessation, the brain suddenly loses GABAergic inhibition while retaining excessive glutamate—the result is seizures, autonomic hyperactivity, and delirium. This is why alcohol and benzodiazepine withdrawal is medically dangerous and why slow tapers with bridging benzodiazepines are necessary.

Epilepsy involves excessive neuronal firing and insufficient GABAergic inhibition. Most anticonvulsants enhance GABA function (valproate increases GABA synthesis; levetiracetam potentiates GABA receptors) or reduce glutamate. Several anticonvulsants are also mood stabilizers (valproate, lamotrigine, carbamazepine), suggesting that mood disorders may involve altered balance between inhibition and excitation.

Glutamate: The Primary Excitatory Neurotransmitter

Glutamate is the main excitatory neurotransmitter. The NMDA (N-methyl-D-aspartate) receptor is a ligand-gated ion channel that requires both glutamate binding and postsynaptic depolarization to open. NMDA receptors are critical for synaptic plasticity and learning but can cause excitotoxicity when overstimulated (contributing to neurodegeneration in stroke, Alzheimer's, Parkinson's). Ketamine and esketamine are NMDA receptor antagonists that block the channel in a use-dependent manner. Their rapid antidepressant effects (within hours) are distinct from SSRIs and suggest a novel mechanism—likely involving increased AMPA receptor trafficking and increased BDNF signaling, which promote neuroplasticity and synaptogenesis.

Memantine, another NMDA antagonist approved for moderate-to-severe Alzheimer's disease, reduces excitotoxic damage by blocking pathological over-stimulation while allowing physiologic activation.

Clinical Correlates: Treatment-Resistant Depression, Dementia, and OCD

Treatment-resistant depression (failure of two or more antidepressants) affects ~30% of depressed patients. Ketamine and esketamine represent a paradigm shift: they work within hours to days (vs. weeks for SSRIs) and are effective in TRD. The mechanism likely involves rapid increase in synaptic plasticity (AMPA receptor increases, BDNF elevation, dendritic spine formation) rather than mere monoamine elevation. Intranasal esketamine is FDA-approved for TRD and depression with suicidality.

In dementia, excitotoxicity contributes to neuronal death. Memantine's NMDA antagonism provides modest cognitive benefits in Alzheimer's by reducing this damage. Some evidence suggests that high-dose glycine (a co-agonist at NMDA receptors) may improve negative symptoms in schizophrenia, though the mechanism is complex.

OCD may involve glutamatergic dysregulation in the orbitofrontal cortex and anterior cingulate cortex (the same regions implicated in the serotonin hypothesis). This motivates interest in glutamate-modulating agents (memantine, topiramate, riluzole) for OCD, with mixed results to date. The glutamate hypothesis of OCD suggests that OCD represents excessive "noise" in the obsession-generating circuits—agents that reduce glutamate transmission could dampen this noise.

Acetylcholine (ACh) System

Muscarinic Receptors and Anticholinergic Effects

Acetylcholine has two major receptor classes: muscarinic (G-protein coupled) and nicotinic (ligand-gated ion channels). Muscarinic M1 receptors in cortex and hippocampus are critical for attention, working memory, and declarative learning. Antagonism of M1 receptors causes the classic anticholinergic side effects: dry mouth, constipation, urinary retention, blurred vision (mydriasis, impaired accommodation), and cognitive impairment. In elderly patients, anticholinergic burden is a major risk factor for delirium, falls, and cognitive decline.

Which psychiatric medications have anticholinergic properties? Tricyclic antidepressants (amitriptyline, nortriptyline) have significant muscarinic antagonism. First-generation antipsychotics (chlorpromazine, fluphenazine) have moderate antagonism. Second-generation antipsychotics vary: clozapine has very high anticholinergic activity (contraindication in narrow-angle glaucoma), while aripiprazole and ziprasidone have minimal activity. Many other medications carry anticholinergic burden: antihistamines (diphenhydramine, hydroxyzine), anticholinergic Parkinson's medications (benztropine, trihexyphenidyl, used to treat antipsychotic-induced EPS), and some urinary antispasmodics.

The anticholinergic burden concept is important in geriatric psychiatry: cumulative anticholinergic effects from multiple medications (e.g., an elderly patient on amitriptyline + benztropine + antihistamine) can produce delirium, urinary retention, acute glaucoma, ileus, and falls. Risk assessment scales (Anticholinergic Cognitive Burden Scale, Beers Criteria) guide medication selection in older adults.

Nicotinic Receptors

Nicotinic receptors in the cortex and hippocampus are involved in attention and learning. Nicotine itself is mildly alerting and may improve attention in ADHD (though not used clinically for this). Varenicline (Chantix), a partial agonist at nicotinic receptors, is used for smoking cessation and works by providing partial nicotine-like stimulation (reducing craving) while blocking full activation by actual cigarette smoke.

Clinical Correlates: Dementia and Delirium

Dementia (particularly Alzheimer's disease) involves loss of cholinergic neurons in the nucleus basalis of Meynert. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)—which prevent ACh breakdown—are used to slow cognitive decline in mild-to-moderate dementia. The mechanism is not reversing the pathology but boosting remaining acetylcholine to improve memory and attention.

Delirium (acute confusion) is frequently triggered or worsened by anticholinergic medications. Medications should be screened for anticholinergic activity, and high-burden agents should be deprescribed when possible. This is especially critical in hospitalized elderly patients where delirium has serious consequences.

Histamine (H1) System

Histamine H1 receptors in the hypothalamus regulate sleep-wake cycling and appetite. H1 antagonism causes sedation and weight gain—two major psychiatric medication side effects. Which medications are potent H1 antagonists? Mirtazapine (extremely potent H1 antagonism, causes sedation and appetite stimulation), low-potency antipsychotics (chlorpromazine, thioridazine, quetiapine at therapeutic doses), olanzapine, and TCAs all have significant H1 antagonism. Ziprasidone, aripiprazole, and lurasidone have minimal H1 antagonism and therefore cause less sedation and weight gain.

The mechanism of weight gain via H1 antagonism involves appetite stimulation and reduced energy expenditure from sedation. First-generation antihistamines (diphenhydramine, hydroxyzine) used for anxiety or insomnia in psychiatric patients also contribute H1 antagonism and weight gain. Clinicians should be aware that some psychiatric medications are literally sedating antihistamines—quetiapine at 25–50 mg is often used off-label as a hypnotic, functioning as little more than an H1-blocking antihistamine at these doses.

Key Brain Regions and Clinical Correlates

Understanding major brain regions and their functions translates neuroscience into clinical practice. Here are the most psychiatrically relevant:

Prefrontal cortex (PFC) is the seat of executive function: planning, decision-making, impulse control, working memory, and cognitive flexibility. It is rich in dopamine and norepinephrine synapses—hence why stimulants and certain antidepressants improve ADHD and depression. PFC dysfunction appears in ADHD (inattention, impulsivity), depression (reduced planning, decision-making paralysis), schizophrenia (negative symptoms, cognitive deficits), and substance use disorder (impaired impulse control, poor decision-making). Psychotherapy and cognitive interventions directly target PFC function.

Amygdala is the brain's threat detector—it processes fear and emotional significance. Amygdala hyperactivity is a core finding in anxiety disorders, PTSD, and BPD. SSRIs and SNRIs reduce amygdala reactivity over weeks via feedback to the amygdala and strengthening of prefrontal-amygdala connections. Exposure therapy (cognitive-behavioral therapy for PTSD, anxiety) directly targets amygdala hyperreactivity by repeated non-reinforced exposure to threat cues, leading to extinction learning. Benzodiazepines rapidly reduce amygdala activation but impair extinction learning if used during therapy—hence the recommendation to taper benzos before starting evidence-based anxiety treatment.

Hippocampus is critical for memory formation and spatial navigation. Volume loss in the hippocampus is found in chronic depression and PTSD, correlating with duration of illness. SSRIs may promote hippocampal neurogenesis (new neuron formation), which contributes to antidepressant effects. Benzodiazepines impair hippocampal memory formation—a major side effect of chronic use.

Basal ganglia (caudate, putamen, globus pallidus, subthalamic nucleus) form the cortico-striato-thalamic-cortical (CSTC) circuits involved in motor control, habit formation, and—notably—the obsessive-compulsive cycle. OCD involves hyperactivity and hyperconnectivity in these circuits. D2 dopamine blockade or serotonin enhancement (SSRI) dampens this hyperactivity. Dysfunction of basal ganglia dopamine in Parkinson's disease causes bradykinesia and rigidity; in tardive dyskinesia (from chronic dopamine blockade), basal ganglia circuits become hypersensitive to dopamine, producing involuntary movements.

Hypothalamus is the command center for the HPA (hypothalamic-pituitary-adrenal) axis, which regulates cortisol in response to stress. HPA hyperactivity is found in depression and PTSD. Antidepressants normalize HPA function over time. The hypothalamus also controls appetite, temperature, and sleep-wake cycling via orexin and histamine neurons—hence why medications affecting these systems cause weight gain and sleep disturbance.

Putting It Together: Medication Selection as Applied Neuroscience

Neuroscience knowledge transforms antidepressant choice from guesswork into logic. Consider three scenarios:

Scenario 1: Depression + insomnia + poor appetite. Standard approach might be sertraline (SSRI), but patient remains insomniac. Neuroscience approach: recognize that this patient has both serotonin deficiency (depression) and hypothalamic/H1 dysfunction (insomnia, appetite loss). Mirtazapine (5-HT2A/2C antagonist + potent H1 antagonist) directly addresses both: serotonin antagonism improves mood, H1 antagonism promotes sleep and appetite. This patient will likely respond better than with SSRI monotherapy.

Scenario 2: Depression + fatigue + poor concentration + anhedonia. This patient's depression appears to center on dopamine deficiency (anhedonia is loss of motivation and pleasure—dopaminergic), not just serotonin. Bupropion (dopamine and norepinephrine reuptake inhibitor) targets this mechanism directly. The SSRI might help mood, but bupropion addresses the anhedonia and cognitive/motivational deficit better. Additionally, bupropion is less likely to cause sexual dysfunction (a common SSRI side effect mediated by serotonergic inhibition in neural circuits supporting sexual response).

Scenario 3: OCD with severe intrusive thoughts unresponsive to standard SSRI doses. OCD requires higher SSRI doses than depression and longer durations to respond. The neuroscience principle: OCD involves glutamate excess in orbitofrontal-anterior cingulate circuits. High-dose SSRI (which indirectly reduces glutamate) or augmentation with a glutamate antagonist (memantine, topiramate, riluzole) might work better than further SSRI escalation. Some patients respond to adding low-dose antipsychotic (5-HT2A and D2 antagonism, reducing downstream glutamate and dopamine hyperactivity in obsessive circuits).

Key Takeaways for Clinicians

Understanding neuroscience does not make psychiatry algorithmic or reductive. Rather, it provides a cognitive framework for reasoning about brain dysfunction and medication effects. When a patient fails to respond to sertraline for depression, the clinician should think: "What other neurotransmitter systems might be dysfunctional here? Is dopamine low (bupropion)? Is norepinephrine low (SNRI, TCA)? Is there a medical cause I've missed?" Conversely, when a patient develops side effects, understanding mechanism allows substitution rather than just raising doses: "This patient has weight gain from olanzapine's H1 antagonism and 5-HT2C antagonism. Can I switch to aripiprazole (minimal H1 antagonism)?" Neuroscience is the lingua franca of modern psychiatry.